What can our experience of traditional bioprocessing teach us about the manufacturing of new cell therapies? TTP’s Edwin Stone was
Autologous cell therapy has had some remarkable clinical success, but to get to where it is today, industry has relied
Part 3: What is the yield of genetic transformation? Genetic engineering of CAR T-cells for therapeutic applications is going through
The benefits of preventive medicine and treating early are well known and a cornerstone of the current UK healthcare system¹.
Autologous cell therapies are unique because they are made in small, individual batches, bespoke to each patient. This places new
Part 2: To what extent can T cells expand in vitro? For cell sorter developers it is critical to specify
Part 1: How many cells are needed in the therapeutic dose? This is a hard question to answer, given the
The amazing results from CAR T-cell therapies for leukaemia in 2013 (Brentjens et al., 2013; Dudley et al., 2013; Grupp